Ostertag revisited: the inherited systemic amyloidoses without neuropathy
- PMID: 16011983
- DOI: 10.1080/13506120500106925
Ostertag revisited: the inherited systemic amyloidoses without neuropathy
Abstract
Mutations in a number of plasma proteins, including transthyretin, apolipoprotein AI, fibrinogen Aalpha-chain, lysozyme, and apolipoprotein AII, are associated with hereditary systemic amyloidosis. Transthyretin amyloidosis is the most common and is usually associated with peripheral neuropathy. Mutations in the other proteins usually have no neuropathic consequences and, instead, cause principally renal and cardiac amyloidosis. Only the apolipoprotein AI glycine 26 arginine mutation may cause peripheral neuropathy and then in only some of the kindreds with this disease. This review is concerned with the non-neuropathic hereditary systemic amyloidoses. It strives to present a synopsis of the present day knowledge of these diseases including each feature of each precursor protein and its mutations; the clinical phenotype of the disease; and suggestions for treatment when feasible. The main objective is to increase awareness of these autosomal dominant diseases, enhance the chances of early diagnosis, enhance the physician's and subsequently the patient's knowledge of each disease, and finally emphasize the need for more research to find ways to treat or prevent these diseases.
Similar articles
-
Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis.J Am Soc Nephrol. 2005 Dec;16(12):3680-6. doi: 10.1681/ASN.2005040382. Epub 2005 Oct 12. J Am Soc Nephrol. 2005. PMID: 16221867
-
Hereditary systemic amyloidosis with renal involvement.J Nephrol. 2003 May-Jun;16(3):443-8. J Nephrol. 2003. PMID: 12832750 Review.
-
A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene.Genomics. 2001 Mar 15;72(3):272-7. doi: 10.1006/geno.2000.6499. Genomics. 2001. PMID: 11401442
-
The hereditary amyloidoses.Best Pract Res Clin Rheumatol. 2003 Dec;17(6):909-27. doi: 10.1016/j.berh.2003.09.001. Best Pract Res Clin Rheumatol. 2003. PMID: 15123043 Review.
-
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.N Engl J Med. 2002 Jun 6;346(23):1786-91. doi: 10.1056/NEJMoa013354. N Engl J Med. 2002. PMID: 12050338
Cited by
-
Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach.PLoS Genet. 2012;8(11):e1003063. doi: 10.1371/journal.pgen.1003063. Epub 2012 Nov 29. PLoS Genet. 2012. PMID: 23209431 Free PMC article.
-
Pathophysiology and treatment of systemic amyloidosis.Nat Rev Nephrol. 2013 Oct;9(10):574-86. doi: 10.1038/nrneph.2013.171. Epub 2013 Aug 27. Nat Rev Nephrol. 2013. PMID: 23979488 Review.
-
Myeloperoxidase-mediated Methionine Oxidation Promotes an Amyloidogenic Outcome for Apolipoprotein A-I.J Biol Chem. 2015 Apr 24;290(17):10958-71. doi: 10.1074/jbc.M114.630442. Epub 2015 Mar 10. J Biol Chem. 2015. PMID: 25759391 Free PMC article.
-
Clinical Outcomes and Disease Burden in Amyloidosis Patients with and Without Atrial Fibrillation-Insight from the National Inpatient Sample Database.J Innov Card Rhythm Manag. 2021 Jun 15;12(6):4542-4549. doi: 10.19102/icrm.2021.120605. eCollection 2021 Jun. J Innov Card Rhythm Manag. 2021. PMID: 34234988 Free PMC article.
-
Construction of a Two-Gene Immunogenomic-Related Prognostic Signature in Lung Squamous Cell Carcinoma.Front Mol Biosci. 2022 Apr 8;9:867494. doi: 10.3389/fmolb.2022.867494. eCollection 2022. Front Mol Biosci. 2022. PMID: 35463955 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials